A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.

[1]  S. Peters,et al.  Eosinophils recruited to the lung by segmental antigen challenge show a reduced chemotactic response to leukotriene B4. , 1994, Prostaglandins.

[2]  D. Woodward,et al.  Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro , 1994, Journal of leukocyte biology.

[3]  W. Busse,et al.  The Effect of Inhibition of 5-Lipoxygenase by Zileuton in Mild-to-Moderate Asthma , 1993, Annals of Internal Medicine.

[4]  S. Peters,et al.  Neutrophils recruited to the lungs of humans by segmental antigen challenge display a reduced chemotactic response to leukotriene B4. , 1993, American journal of respiratory cell and molecular biology.

[5]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[6]  P. Weller,et al.  Mechanisms of eosinophil recruitment. , 1993, American journal of respiratory cell and molecular biology.

[7]  S. Peters,et al.  Immunoglobulin E-mediated increase in vascular permeability correlates with eosinophilic inflammation. , 1993, The American review of respiratory disease.

[8]  R. deShazo.  Bronchoalveolar Lavage in Asthma , 1993 .

[9]  S. Peters,et al.  Effect of antigen dose on the recruitment of inflammatory cells to the lung by segmental antigen challenge. , 1992, The Journal of allergy and clinical immunology.

[10]  W. Busse,et al.  Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. , 1991, The American review of respiratory disease.

[11]  M. Chan-yeung,et al.  Differences in mediator release between allergic rhinitis and asthma. , 1991, The Journal of allergy and clinical immunology.

[12]  L. Dubé,et al.  Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. , 1991, Agents and actions. Supplements.

[13]  H. Knapp,et al.  Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. , 1990, The New England journal of medicine.

[14]  Paul H. Rubin,et al.  The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. , 1990, The New England journal of medicine.

[15]  S. Rennard,et al.  Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. , 1989, The American review of respiratory disease.

[16]  A. Wardlaw,et al.  Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. , 1989, The Journal of allergy and clinical immunology.

[17]  S. Charleson,et al.  Measurement of urinary leukotrienes by reversed-phase liquid chromatography and radioimmunoassay. , 1989, Clinical chemistry.

[18]  S. Wenzel,et al.  Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. , 1989, The American review of respiratory disease.

[19]  K. Frank Austen,et al.  Local Effects of Synthetic Leukotrienes (LTC4, LTD4, and LTB4) in Human Skin , 1983 .

[20]  M. A. Bray.  The pharmacology and pathophysiology of leukotriene B4. , 1983, British medical bulletin.

[21]  Bengt Samuelsson,et al.  Leukotrienes are potent constrictors of human bronchi , 1980, Nature.

[22]  M. A. Bray,et al.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes , 1980, Nature.

[23]  J. E. Scott,et al.  A RAPID AND PRECISE METHOD FOR THE DETERMINATION OF UREA , 1960, Journal of clinical pathology.

[24]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.